NCT07024823View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

PHASE1RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Chronic Kidney Disease
Interventions
DRUG

AZD4248

AZD4248 will be administered orally.

DRUG

Placebo

Placebo will be administered orally.

DRUG

AZD4248

AZD4248 will be administered via IV infusion.

DRUG

Placebo

Placebo will be administered via IV infusion.

Trial Locations (5)

48109

RECRUITING

Research Site, Ann Arbor

55114

RECRUITING

Research Site, Saint Paul

60643

RECRUITING

Research Site, Chicago

78215

RECRUITING

Research Site, San Antonio

91206

RECRUITING

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY